Remote Assessment: IDH Status Changes Everything
The most critical piece of information in astrocytoma is IDH mutation status, because IDH-mutant astrocytoma is a distinct disease with a markedly better prognosis than the far more aggressive IDH-wildtype glioblastoma. For this reason, in an international assessment we ask you to share, alongside your MRI, any pathology and molecular results (IDH, ATRX, TP53, CDKN2A/B) via WhatsApp; if these are not available, a preliminary framework is drawn with the MRI at hand. In this online opinion, the tumor's features, the suitability of surgery and whether traveling to Turkey is meaningful for your situation are discussed honestly.
What Is Astrocytoma?
Astrocytoma is a primary brain tumor that develops from astrocytes, the supporting cells of the brain, and accounts for roughly one third of all primary brain tumors. The well-behaved pilocytic astrocytoma predominates in children, while the infiltrating diffuse astrocytomas predominate in adults. The 2021 WHO classification redefined adult diffuse gliomas by IDH status: IDH-mutant astrocytoma is now considered a single tumor type, graded 2, 3 or 4, and carries a markedly better prognosis than IDH-wildtype glioblastoma. For this reason a diagnosis of 'astrocytoma' alone is not a treatment prescription; grade and molecular profile are decisive. In an international patient, clarifying this profile is the foundation of the plan.
The Decision Is Individualized by IDH Status and Grade
Treatment is individualized by grade, IDH status, molecular profile, tumor location and overall condition. The first step is usually the widest safe surgical resection. For low-grade IDH-mutant tumors, options after surgery include close MRI surveillance, the brain-penetrant IDH inhibitor vorasidenib (approved for certain grade 2 cases after surgery), and radiotherapy with chemotherapy when needed. For higher-grade cases, radiotherapy and chemotherapy (temozolomide or PCV) are added to surgery. In the presence of microvascular proliferation, necrosis or homozygous CDKN2A/B deletion, the tumor is considered grade 4 regardless of histology. For an international patient, which part of this treatment chain is delivered in Turkey and which in the home country is planned multidisciplinarily from the outset.
The Treatment Journey in Turkey and Preserving Function
Because astrocytoma infiltrates the surrounding brain, the aim of surgery is the widest possible resection while preserving function; the volume removed influences survival and time to recurrence, while the function preserved determines quality of life. If surgery is found appropriate after the remote opinion, the date and estimated length of stay are planned before your arrival. In Turkey, neuronavigation, functional MRI and DTI tractography, and awake craniotomy with cortical mapping when needed, are used to strike this balance. After surgery there is usually 24-48 hours of intensive care and a few days in hospital; the extent of resection is assessed with a control MRI, and the pathological-molecular result is provided in writing for continuation treatment in your home country.
Prognosis, Realistic Expectations and Multilingual Communication
One of the strongest determinants of prognosis is IDH mutation status; survival in IDH-mutant astrocytomas is markedly longer than in IDH-wildtype glioblastoma and varies by grade. Because low-grade tumors may transform to higher grade over time, close MRI follow-up is important. The risks of surgery (bleeding, infection, a temporary/permanent deficit, edema, seizures) are discussed openly. For a patient coming from across a border, the most important point is that these expectations and the long-term follow-up plan are clearly understood in their own language. We make no guaranteed promises; each patient's course is different, and expectations are shared openly from the start.